World

I took anti-malarial drug HCQ for a week as preventive measure: Trump

Prashasti Awasthi Mumbai | Updated on May 19, 2020 Published on May 19, 2020

US President Donald Trump speaks during a news conference. (File photo)   -  Bloomberg

United States President Donald Trump took the whole world by surprise when he disclosed that he has been taking anti-malarial drug hydroxychloroquine for a week. The malarial drug has not been approved by Trump’s own administration, Agence France Presse reported.

Trump said that he has been taking this drug as a preventive measure “for about a week and a half.” However, Trump has shown no symptoms of the virus and was tested negative for it.

"I take a pill every day," he said, adding that he combines this with zinc. When the reporters asked him the reason behind his intake, he said: "Because I think it's good. I've heard a lot of good stories."

Trump seems to have been fixated on the drug and promoting its use, even if some doctors think it does not work for coronavirus patients and US government regulators warn it has "not been shown to be safe."

"You'd be surprised at how many people are taking it, especially the front-line workers before you catch it. The front-line workers -- many, many are taking it. I happen to be taking it," he said to reporters attending a White House meeting devoted to the struggling restaurant industry.

"I'm taking it, hydroxychloroquine, right now, yeah. A couple of weeks ago, I started taking it," he said as cited in the AFP report.

Trump informed that his dosage of the medicine was approved by the White House physician. However, he later said that he, not the doctor, took the first step.

"I asked him, 'what do you think?' He said, 'if you'd like it.' I said 'yeah, I'd like it.'"

Trump further noted that he has received many "positive calls" from people, whom he did not identify, telling him about the malaria drug. He mentioned a letter he'd received from a New York doctor, also unidentified, who reported giving the medicine to hundreds of patients and "I haven't lost one."

However, the government's Food and Drug Administration has warned against the intake of the hydroxychloroquine for either prevention or treatment of the coronavirus. It has noted the side effects including "serious heart rhythm problems in patients with Covid-19." Only emergency use is authorized under temporary rules, AFP report added.

Earlier this month, a medical paper out of New York suggested that combining hydroxychloroquine with the dietary supplement zinc sulfate, which has antiviral properties, could create a more effective treatment against coronavirus.

 

Published on May 19, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.